- Home
- PLYM vs DNTH Comparison
PLYM vs DNTH Comparison
Compare PLYM & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLYM
- DNTH
- Stock Information
- Founded
- PLYM 2011
- DNTH 2015
- Country
- PLYM United States
- DNTH United States
- Employees
- PLYM N/A
- DNTH N/A
- Industry
- PLYM Real Estate Investment Trusts
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- PLYM Real Estate
- DNTH Health Care
- Exchange
- PLYM Nasdaq
- DNTH Nasdaq
- Market Cap
- PLYM 732.4M
- DNTH 606.2M
- IPO Year
- PLYM 2017
- DNTH N/A
- Fundamental
- Price
- PLYM $14.45
- DNTH $21.50
- Analyst Decision
- PLYM Buy
- DNTH Strong Buy
- Analyst Count
- PLYM 9
- DNTH 8
- Target Price
- PLYM $21.44
- DNTH $53.00
- AVG Volume (30 Days)
- PLYM 338.4K
- DNTH 371.6K
- Earning Date
- PLYM 08-06-2025
- DNTH 08-11-2025
- Dividend Yield
- PLYM 6.64%
- DNTH N/A
- EPS Growth
- PLYM 600.05
- DNTH N/A
- EPS
- PLYM 3.05
- DNTH N/A
- Revenue
- PLYM $180,505,000.00
- DNTH $6,524,000.00
- Revenue This Year
- PLYM $2.17
- DNTH N/A
- Revenue Next Year
- PLYM $10.13
- DNTH N/A
- P/E Ratio
- PLYM $4.74
- DNTH N/A
- Revenue Growth
- PLYM N/A
- DNTH 102.36
- 52 Week Low
- PLYM $12.70
- DNTH $13.37
- 52 Week High
- PLYM $24.70
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- PLYM 29.24
- DNTH 58.34
- Support Level
- PLYM $14.05
- DNTH $20.00
- Resistance Level
- PLYM $15.93
- DNTH $23.21
- Average True Range (ATR)
- PLYM 0.35
- DNTH 1.28
- MACD
- PLYM -0.12
- DNTH -0.05
- Stochastic Oscillator
- PLYM 18.43
- DNTH 58.09
About PLYM Plymouth Industrial REIT Inc.
Plymouth Industrial REIT Inc is a full-service, vertically integrated, self-administered, and self-managed Maryland corporation. It is focused on the acquisition, ownership, and management of single and multi-tenant Class B industrial properties, including distribution centers, warehouses, and light industrial properties, located in secondary and primary markets across the United States. The company has one reportable segment, which is Industrial properties. The majority of its property portfolio is spread across Florida, Ohio, Indiana, Tennessee, Illinois and Georgia, among others. It receives income from the rental revenue through its properties.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.